Literature DB >> 15851612

Defective cardiac ryanodine receptor regulation during atrial fibrillation.

John A Vest1, Xander H T Wehrens, Steven R Reiken, Stephan E Lehnart, Dobromir Dobrev, Parag Chandra, Peter Danilo, Ursula Ravens, Michael R Rosen, Andrew R Marks.   

Abstract

BACKGROUND: Ca2+ leak from the sarcoplasmic reticulum (SR) may play an important role in triggering and/or maintaining atrial arrhythmias, including atrial fibrillation (AF). Protein kinase A (PKA) hyperphosphorylation of the cardiac ryanodine receptor (RyR2) resulting in dissociation of the channel-stabilizing subunit calstabin2 (FK506-binding protein or FKBP12.6) causes SR Ca2+ leak in failing hearts and can trigger fatal ventricular arrhythmias. Little is known about the role of RyR2 dysfunction in AF, however. METHODS AND
RESULTS: Left and right atrial tissue was obtained from dogs with AF induced by rapid right atrial pacing (n=6 for left atrial, n=4 for right atrial) and sham instrumented controls (n=6 for left atrial, n=4 for right atrial). Right atrial tissue was also collected from humans with AF (n=10) and sinus rhythm (n=10) and normal cardiac function. PKA phosphorylation of immunoprecipitated RyR2 was determined by back-phosphorylation and by immunoblotting with a phosphospecific antibody. The amount of calstabin2 bound to RyR2 was determined by coimmunoprecipitation. RyR2 channel currents were measured in planar lipid bilayers. Atrial tissue from both the AF dogs and humans with chronic AF showed a significant increase in PKA phosphorylation of RyR2, with a corresponding decrease in calstabin2 binding to the channel. Channels isolated from dogs with AF exhibited increased open probability under conditions simulating diastole compared with channels from control hearts, suggesting that these AF channels could predispose to a diastolic SR Ca2+ leak.
CONCLUSIONS: SR Ca2+ leak due to RyR2 PKA hyperphosphorylation may play a role in initiation and/or maintenance of AF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851612     DOI: 10.1161/01.CIR.0000162461.67140.4C

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  130 in total

Review 1.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

Review 3.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 4.  [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

Authors:  M Hammwöhner; A D'Alessandro; D Dobrev; P Kirchhof; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

5.  Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes.

Authors:  Y-J Chen; Y-C Chen; W Wongcharoen; C-I Lin; S-A Chen
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 6.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

7.  Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation.

Authors:  David Y Chiang; Na Li; Qiongling Wang; Katherina M Alsina; Ann P Quick; Julia O Reynolds; Guoliang Wang; Darlene Skapura; Niels Voigt; Dobromir Dobrev; Xander H T Wehrens
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

8.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

Review 9.  Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases.

Authors:  David L Beavers; Andrew P Landstrom; David Y Chiang; Xander H T Wehrens
Journal:  Cardiovasc Res       Date:  2014-06-15       Impact factor: 10.787

Review 10.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.